ArticleBiologia futura2026
Biological potential of an antibacterial substance from Mammaliicoccus sciuri isolated from sheep milk.
Article in Biologia futura, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing threat of antibiotic resistance underscores the urgent need to investigate alternative antimicrobial agents, including bacteriocins or bacteriocins like peptides. The purpose of the present work was to isolate and characterize bacteria from sheep milk that produce antibacterial substances. A strain identified as Mammaliicoccus sciuri 1SH was isolated and its extracellular peptides were extracted and partially purified by ethyl acetate. Sodium dodecyl sulphate poly acrylamide gel electrophoresis (SDS-PAGE) analysis revealed a substance with a molecular weight of about 70 kDa. Activity was characterized across varying pH (2.5-8.5) and temperature (25-80 °C) ranges, demonstrating optimal activity between 25-37 °C and pH 6.5-7.4. Enzyme treatment with pepsin and pancreatin significantly reduced the activity, confirming its proteinaceous nature. The antibacterial substance demonstrated antibacterial activity against 26 clinical isolates of Escherichia coli, with minimum inhibitory concentration (MIC) values ranging from 1.125-70 µg/mL and minimum bactericidal concentration (MBC) 6.5-75 µg/mL. Growth kinetic tests demonstrated that growth of Escherichia. coli was suppressed in a dose-dependent way. Mechanistic studies revealed that the peptide induces DNA and protein leakage, indicating membrane disruption as a potential mode of action. Furthermore, the peptide demonstrated significant anti-oxidant activity (IC
Indexed as
Identifiers
42126801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.